Mawi launches Mawi Heart Patch

October 3, 2022 — Mawi, creators of AI-powered wearable medical devices for cardiac disease diagnostic and monitoring, announced today the official launch of Mawi Heart Patch, the first-ever, single-use 2-lead cardiac monitor to reach the market. A stick-and-go, wireless solution, Mawi Heart Patch improves the detection of cardiovascular diseases, the world’s leading cause of death, by 3x. Providing a detailed report within 24 hours after monitoring is complete, the solution reduces time to diagnosis by 97% and ensures patients get timely access to life-saving treatment. 

Currently, cardiologists rely on Holter monitors made up of multiple wires or multi-use single-lead patches that impact the wearer’s quality of life. These devices are prone to dislodging, peeling and causing allergic reactions, thus restricting monitoring time. As a result, more than 50% of arrhythmias go undetected. Moreover, patients have to wait up to a month to receive the results. Multi-use monitors also require pre- and post-service maintenance, such as changing electrodes and sanitization, before they can be reused, which demands considerable time and resources. These expensive monitors also require significant upfront investment, so facilities typically only have a few available. In limited supply, devices are reserved for a part of those with clear and obvious signs of heart disease, prohibiting those that appear relatively healthy from receiving an early diagnosis before their condition becomes life-threatening. 

The Mawi Heart Patch is the first single-use product to provide an efficient and effective way to detect cardiovascular conditions, enabling healthcare practices to provide timely monitoring to all patients in need. The comfortable, lightweight and discreet sensor can be applied in under 60 seconds and patients can live as normal - work out, take showers and sleep without experiencing discomfort while the AI under the hood powered by a 2-lead ECG technology scans every beat to detect critical abnormalities. This mitigates the ‘white coat effect’ - where the presence of the device skews a patient’s vital metrics - and enables patients to stay relaxed as they go about their routine, making it easier to detect potential problems. Continuously monitoring for up to 7 days, the patch significantly improves the reliability of results with research showing week-long monitoring is x3 more likely to lead to the detection of abnormalities.  

As a single-use product, the patch is fully disposable and doesn’t require any pre- or post-service maintenance, enabling medical facilities to provide large-scale monitoring to all patients showing signs of potentially fatal heart disease. Mawi only charges a fee for service, so practices can scale without initial investment in equipment and software. 

“Cardiovascular diseases pose the greatest risk to our long-term health and are the leading cause of death globally. With a lack of or ineffective monitoring often proving critical, many of these deaths can be avoided with the right preventative measures,” Andrew Klymenko, co-founder of Mawi, said. “Too often, sufferers do not realise the severity of their symptoms before it’s too late. Many patients that use the Mawi Heart Patch look healthy, exercise daily and show no signs of disease, yet have a potentially lethal heart condition. In many cases, conditions aren’t caught in time when relying on outdated cardiac monitors and with lengthy delays to diagnosis. Here, the Mawi Heart Patch is a lifesaver. We’re on a mission to prevent the heart’s ‘silent killers’, and we’re already working with like-minded clinics that are seeing amazing results.” 

For more information: www.mawiheart.com